乐天堂FUN88

In China, For Global

An innovative and globally competitive

biopharmaceutical company with a whole-indu⛦stry-chain layou💧t.

In China, For Global

An innovative and globally competitive

biopharmace❀utical company with a whole-industry-chain layout.

Original Innovation, Science Oriented

Globally-integrated R&D process

Technolog🅠y system encompassinꩵg the entire lifecycle of antibodies

Innovation-driven Biopharma

China’s leading innovative bi🔯opharmaceuౠtical company

Established in December, 2012

Therapeutic Area

  • Oncology

    Toripalimab (PD-1), Tifcemalimab (BTLA)…

  • Autoimmune

    Adalimumab (TNF-α), JS005 🍌(IL-17A), UBP1213sc (BLyS)

  • Metabolic

    Ongericimab (PCSK9), JS103 (Uricase), JS401 (ANGPTL𓄧3)…

  • Neurological

    JS010 (CGRP)

  • Infectious

    Etesevimab (S protein), Deuremidevi🤪r Hydrobromide (RdRp)…

Therapeutic Area

  • Oncology
  • Autoimmune
  • Metabolic
  • Neurological
  • Infectious
Learn more

Our Milestones

News Center

  • Apr 7, 2024

    Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Li🎀ne Treꦬatment of Renal Cancer

    >The NMPA has approved the supplemental new drug application for toripalimab in combination with axitinib for the first-line treatment of patients witꦕh medium to high risk unresectable or metastatic renal cell carcinoma

    View details
  • Jan 2, 2024

    Junshi Biosciences Announces Approval of the Supplemental New🐠 Drug Application for Toripalimab as Perioperative Treatment for Resectable෴ NSCLC Patients

    >The supplemental new drug application for toripalimab in combination with chemotherapy as perioperative treatment and subsequently, monotherapy as adjuvant therไapy for the treatment of adult patients with resectable stage IIIA-IIIB non-small cell lung cancer has been approved by the National Medical Products Administration

    View details
  • Dec 1, 2023

    Junshi Biosciences Announces New ♔Chemi⛎cal Entity Application for Toripalimab Accepted by Australia’s TGA

    >Therapeutic Goods Administration of the Australian Government Department of Health and Aged Care (TGA) has accepted the New Chemical Entity (NCE) application for toripalimab in c🌞ombination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and for toripalimab, as a single agent, for the treatment of ad💛ults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy

    View details
  • Oct 29, 2023

    Junshi Biosciences Announces FDA Approval of LOQTORZI™ (toripalimab-tpziᩚᩚᩚᩚᩚᩚ⁤⁤⁤ꦆ⁤ᩚ⁤⁤⁤⁤ᩚ⁤⁤⁤⁤ᩚ𒀱ᩚᩚᩚ) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

    >The U.S. FDA approved LOQTORZI (toripalimab-tpzi) in combination with cisplatin and gemcitabine for the first-line treatmeꦯnt 💝of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy

    View details
Join us

"Provide 🐬patients with world-class, trustworthy, affordable, and innovative drugs"

View details